$KTRA Still way undervalued. Even if mgmt were to exercise all $25M worth of private placement today (unlikely!), That would value KTRA only ~$40M for VAL-083, a potential best in class drug that prior p2 data has shown beats SOC Temo in mOS (16.5mo VAL-083 vs. 12.7-16.0mo Temo). KTRA should trade ~$2 before AGILE-GBM data readout. And if +ve data, more than double to $5+. ☘️💎
1
3
3 Likes